Evotec Results Presentation Deck

evotec Revenues from contracts with customers (in € m) Base revenues Milestones, upfronts and licences PAGE 10 231.0 7.8 223.2 H1 2020 +17% +17% Gross margin affected by ongoing capacity build-up - as planned Revenues & Gross margin overview - Evotec SE and subsidiaries 271.3 10.0 261.3 H1 2021 Gross margin (in %) Total Margin Margin excl. milestones, upfronts and licences and amortisation 23.0 23.4 H1 2020 20.8 19.4 H1 2021 • Base revenues up 17% or € 38.1 m to € 261.3 m. Adjusted for anticipated end of Sanofi subsidy and unfavourable fx effects growth would have reached 22% • Just - Evotec Biologics added revenues of € 23.0 m, increase of 44% Despite higher year-on-year milestone revenues of € 4.1 m (H1 2020: € 2.2 m), some milestone payments still delayed due to COVID-19, but imminent • Gross margin decreased mainly due to capacity build-up ahead of launch of J.PODⓇ 1 US in Q3 and fx

View entire presentation